Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Harriette Van Spall , Udo Bavendiek Added: 7 months ago
ESC Congress 2025 - Digitoxin reduced the risk of all-cause mortality and hospitalisation in patients with worsening heart failure.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Udo Bavendiek to explore the DIGIT-HF trial, investigating whether digitoxin can improve outcomes in patients with advanced chronic heart failure and reduced ejection fraction.This landmark study… View more
Added: 6 months ago Source:  Radcliffe Cardiology
AUTHOR: Jordan RanceRisk stratification for primary prevention implantable cardioverter-defibrillator (ICD) placement in patients with cardiac sarcoidosis remains a clinical challenge, partly due to inconsistencies in diagnostic criteria and the variable course of the disease. A new study published in the European Heart Journal suggests that cardiovascular magnetic resonance (CMR) phenotyping has… View more
Author(s): Finn Gustafsson Added: 1 year ago
HFA 24 - Dr Finn Gustafsson (Rigshospitalet, DK) joined us onsite at the Heart Failure Association Congress to discuss the findings from a subanalysis of the ARIES HeartMate 3 study (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two… View more
Author(s): Michael R Zile Added: 1 year ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had… View more